Replies to post #767784 on NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

There are companies in the oncology space that are consistently valued at under $300-400M market cap, several quarters after FDA approval (despite US being 10X the market potential of UK’s MHRA). And NWBO will join that club of poorly run companies as well. No big pharma is interested in NWBO, just like some of these other companies.

No excuses when LP dilutes in pennies post UK approval and that no big pharma injects cash, OK?

[biosectinvestor]

Plus the company is not for sale. I don’t think they will sell until pricing would reflect the ultimate value. I have mentioned it before and another poster posted on this today, but Regeneron was in development for its first drug over 2 decades. It had a former CEO of Merck and multiple Nobel laureates leading it and writing about it, yet it was a loser, until it wasn’t. It is still independent to this day and a great company. But it went through hell getting its first big drug to market. And it’s still independent.

Buyouts are not everything. Shorts know that. They just use buyouts and deals as a way to make people feel defensive about owning stocks like NWBO. Of course it would be great to have a source of non-dilutive funds. But that won’t determine long-term success, one way or the other, at this point. DCVax-L appears headed for official UK approval and there is not a lot shorts can do but work day and night to undermine the story, as long as possible and try to keep the market from seeing it as a “success”, even with approval. That’s their game.